Home HOME Neoplasma 2022 Neoplasma Vol.69, No.2, p.474–483, 2022

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.69, No.2, p.474–483, 2022

Title: Novel biochemical markers for non-invasive detection of pancreatic cancer
Author: Pavel Hrabák, Jan Šoupal, Marta Kalousová, Tomáš Krechler, Michal Vočka, Tomáš Hanuš, Luboš Petruželka, Štěpán Svačina, Aleš Žák, Tomáš Zima

Abstract: To identify non-invasive biomarkers of non-metastatic pancreatic cancer (PC) blood from 186 patients (PC n = 28; DM-diabetes mellitus n = 60; ChP-chronic pancreatitis n = 47; healthy controls n = 51) was analyzed for 58 candidate biomarkers. Their effectiveness to identify PC was compared with CA19-9. Panel defined by Random-forest (RF) analysis (CA19-9, AAT, IGFBP2, albumin, ALP, Reg3a, HSP27) outperforms CA 19-9 in discrimination of PC from DM (AUC 0.92 vs. 0.82). Panel (S100A11, CA72-4, AAT, CA19-9, CB, MMP-7, S100P-s, Reg3a) is better in discrimination PC from ChP than CA19-9 (AUC 0.90 vs. 0.75). Panel (MMP-7, Reg3a, sICAM1, OPG, CB, ferritin) is better in discrimination PC from healthy controls than CA 19-9 (AUC 0.89 vs. 0.78). Panel (CA19-9, S100P-pl, AAT, albumin, adiponectin, IGF-1, MMP7, S100A11) identifies PC among other groups better than CA19-9 (AUC 0.91 vs. 0.80). Panel defined by logistic regression analysis (prealbumin, IGFBP-2, DJ-1, MIC-1, CA72-4) discriminates PC from DM worse than CA19-9 (AUC 0.80 vs. 0.82). Panel (IGF-1, S100A11, Reg1alfa) outperforms CA19-9 in discrimination PC from ChP (AUC 0.76 vs. 0.75). Panel (IGF-2, S100A11, Reg3A) outperforms Ca19-9 in discrimination PC from healthy controls (AUC 0.95 vs. 0.78). Panel (albumin, AAT, S100P-serum, CRP, CA19-9, TFF1, MMP-7) outperforms CA19-9 in identification PC among other groups (AUC 0.89 vs. 0.8). The combination of biomarkers identifies PC better than CA19-9 in most cases. S100A11, Reg3A, DJ-1 were to our knowledge identified for the first time as possible serum biomarkers of PC.

Keywords: serum biomarker; pancreatic cancer; non-invasive diagnosis; panel of biomarkers; S100 proteins family
Published online: 11-Feb-2022
Year: 2022, Volume: 69, Issue: 2 Page From: 474, Page To: 483
Price: 21.00 €

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.